1Q22 Earnings Presentation

Q1 FY2022 Earnings

October 28, 2021

Presentation of financial information & forward-looking statements

Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated.

This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.resmed.com).

In addition to historical information, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed's current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, and tax outlook. Forward-looking statements can generally be identified by terminology such as "may", "will", "should", "expects", "intends", "plans", "anticipates", "believes", "estimates", "predicts", "potential", or "continue", or variations of these terms, or the negative of these terms or other comparable terminology.

ResMed's expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the "Risk Factors" identified in ResMed's quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements.

2 © 2021 ResMed | Q1 2021 Earnings Presentation - Oct 28, 2021

Our mission is to change 250 million lives in 2025

We're proud to offer digital and connected health solutions that help those with sleep apnea, COPD, and other respiratory diseases live happier, healthier lives in the comfort of home or care setting of their choice

During the last 12 months, we changed over 130 million lives with our digital health products and cloud-based software solutions

ResMed | The global leader in connected and digital health

Key Statistics1

Headquarters		San Diego, CA
Founded	1989
LTM 1Q22 revenue		$3.2B
Listed (NYSE, ASX)		1995, RMD
Market cap		~$40B
Countries served	140+
Total employees	~8,000

11%

11%

	Revenue		Revenue
37%	by business 52%	35%	by region 54%
LTM 1Q22	LTM 1Q22

	Devices	 U.S., Canada, and Latin America
	Masks & Other		Europe, Asia, and Other
	OOH SaaS		U.S. SaaS

	Sleep Apnea	Respiratory Care	Software as a Service (SaaS)
Our	Delivering a market-leading patient	Improving the lives of patients with COPD,	Providing a network out-of-hospital healthcare
businesses	experience through innovative solutions that	asthma, and other key chronic respiratory	SaaS management solutions that help providers
lower overall costs for treating sleep apnea	diseases on their healthcare journey -	deliver more personalized care, measurable
	patients and improve clinical outcomes by	lowering costs, preventing hospitalization,	results, and improved health outcomes across
	leveraging global digital health solutions	and creating end-to-end care solutions	large populations

1As of 9/30/2021

4 © 2021 ResMed | Q1 2021 Earnings Presentation - Oct 28, 2021

ResMed 2025: a patient-centric,digitally-enabled strategy

250 million lives improved in out-of-hospital healthcare in 2025!

Purpose Empower people to live happier, healthier, and higher quality lives in the comfort of their home

Growth Focus Global health epidemics in sleep apnea, COPD, other major chronic conditions, and SaaS solutions that improve care in out-of-hospital settings

Growth Advantage Transform care through innovative solutions and tech-drivenintegrated care to drive superior outcomes, experiences, and efficiency

Growth Foundations High-performing, diverse, and entrepreneurial people

Industry-leading innovation and business excellence

Digital health technology and scientific leadership

5 © 2021 ResMed | Q1 2021 Earnings Presentation - Oct 28, 2021